Statin therapy is associated with epigenetic modifications in individuals with Type 2 diabetes.
Silja SchraderAlexander PerfilyevMats MartinellSonia García-CalzónCharlotte LingPublished in: Epigenomics (2021)
Aim: Statins lower cholesterol and reduce the risk of cardiovascular disease. However, the exact mechanisms of statins remain unknown. We investigated whether statin therapy associates with epigenetics in Type 2 diabetes (T2D) patients. Materials & methods: DNA methylation was analyzed in blood from newly diagnosed T2D patients in All New Diabetics in Scania (ANDIS) and a replication cohort All New Diabetics in Uppsala County (ANDiU). Results: Seventy-nine sites were differentially methylated between cases on statins and controls (false discovery rate <5%) in ANDIS. These include previously statin-associated methylation sites annotated to DHCR24 (cg17901584), ABCG1 (cg27243685) and SC4MOL (cg05119988). Differential methylation of two sites related to cholesterol biosynthesis and immune response, cg17901584 (DHCR24) and cg23011663 (ARIH2), were replicated in ANDiU. Conclusion: Statin therapy associates with epigenetic modifications in T2D patients.
Keyphrases
- cardiovascular disease
- newly diagnosed
- dna methylation
- end stage renal disease
- type diabetes
- immune response
- ejection fraction
- chronic kidney disease
- coronary artery disease
- gene expression
- peritoneal dialysis
- mass spectrometry
- low density lipoprotein
- small molecule
- metabolic syndrome
- high throughput
- patient reported outcomes
- adipose tissue
- drug induced
- density functional theory
- copy number